Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2013,（2）
• 页码范围: 212-213
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2012.145

摘要

Glutamate is extensively involved in metabolic and oncogenic pathways.Univariate and multivariate analyses showed that serum glutamate levels directly correlated with Gleason score (≤ 6 vs.≥ 8) and primary prostate cancer (PCa) aggressiveness.Compared with Caucasian Americans,serum glutamate levels were higher in African Americans with metastatic castrateresistant PCa than in the patients with primary tumors.Glutamate deprivation or blockade with pharmacological inhibitors of glutamate release or metabotropic glutamate receptor 1 (GRM1) decreased growth,migration and invasion,and induced apoptosis in both androgen-stimulated and androgenindependent PCa cells.Immunohistochemical staining showed GRM1 overexpression in primary or metastatic PCa tissues.These data highlight the potential of glutamate as a biomarker of aggressiveness in primary PCa and target its metabolic and signaling activities for therapeutic interventions.